The rapid FEV1 decline in chronic obstructive pulmonary disease is associated with predominant emphysema: A longitudinal study

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 1, 2013, Pages 55-61

  Cerveri, Isa ^a   Corsico, Angelo G ^a   Grosso, Amelia ^a   Albicini, Federica ^a   Ronzoni, Vanessa ^a   Tripon, Bianca ^a   Imberti, Federica ^a   Galasso, Thomas ^a   Klersy, Catherine ^b   Luisetti, Maurizio ^a   Pistolesi, Massimo ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Computed tomography; Follow up studies; Hyperinflation; Lung function decline

Indexed keywords

BUDESONIDE; FLUTICASONE; FORMOTEROL; SALMETEROL; TIOTROPIUM BROMIDE;

AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HIGH RESOLUTION COMPUTED TOMOGRAPHY; HOSPITALIZATION; HUMAN; HYPERINFLATION; INTERVIEW; LONGITUDINAL STUDY; LUNG EMPHYSEMA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; CONFIDENCE INTERVAL; DISEASE COURSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; RADIOGRAPHY; RISK; RISK FACTOR; SMOKING;

AGED; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESIDUAL VOLUME; RISK FACTORS; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84874098071     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.727920     Document Type: Article

References (31)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD, updated 2011. Available from http://www.goldcopd.org/Guidelines/guidelines-resources.html
2. Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet 2009; 374(9691):670-672.
3. Agusti A, Calverley PM, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.
4. Anderson D, Macnee W. Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis 2009; 4:321-335.
5. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36(3):531-539.
6. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008; 102(3):367-376.
7. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34(4):812-818.
8. Weatherall M, Shirtcliffe P, Travers J, et al. Use of cluster analysis to define COPD phenotypes. Eur Respir J 2010; 36(3):472-474.
9. Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 2006; 119(10 Suppl 1):4-11.
10. Devanarayan V, Scholand MB, Hoidal J, et al. Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD. COPD 2010; 7(1):51-58.
11. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26(2):319-338.
12. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volume and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.
13. Goddard PR, Nicholson EM, Laszlo G, et al. Computed tomography in pulmonary emphysema. Clin Radiol 1982; 33(4):379-387.
14. Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 1(7442):830-835.
15. Calverly PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362(9389):1053-1061.
16. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010; 182(5):598-604.
17. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365(13):1184-1192.
18. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185(1):44-52.
19. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374(9696):1171-1178.
20. Celli BR, Thomas NE, Anderson JA, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185(1):44-52.
21. Fletcher C, Peto R et al. The natural history of chronic airflow obstruction. Br Med J 1977; 1(6077):1645-1648.
22. Yuan R, Hogg JC, Paré PD, et al. Prediction of the rate of decline in FEV(1) in smokers using quantitative Computed Tomography. Thorax 2009; 64(11):944-949.
23. Remy-Jardin M, Edme JL, Boulenguez C, et al. Longitudinal follow-up study of smoker's lung with thin-section CT in correlation with pulmonary function tests. Radiology 2002; 222(1):261-270.
24. Stolk J, Putter H, Bakker EM, et al. Progression parameters for emphysema: a clinical investigation. Respir Med 2007; 101(9):1924-1930.
25. Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010; 138(3):635-640.
26. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8):545-555.
27. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-Analysis. Thorax 2003; 58(11):937-941.
28. van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166(10):1358-1363.
29. Camiciottoli G, Bartolucci M, Maluccio NM, et al. Spirometrically gated high-resolution CT findings in COPD: lung attenuation vs lung function and dyspnea severity. Chest. 2006; 129(3):558-564.
30. Cerveri I, Dore R, Corsico A, et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004; 125(5):1714-1718.
31. Cavigli E, Camiciottoli G, Diciotti S, et al. Whole-lung densitometry versus visual assessment of emphysema. Eur Radiol 2009; 19(7):1686-1692.